Shanghai MicuRx Pharmaceutical Co. Ltd. A
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resi… Read more
Shanghai MicuRx Pharmaceutical Co. Ltd. A - Asset Resilience Ratio
Shanghai MicuRx Pharmaceutical Co. Ltd. A (688373) has an Asset Resilience Ratio of 32.76% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Shanghai MicuRx Pharmaceutical Co. Ltd. A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Shanghai MicuRx Pharmaceutical Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥253.18 Million | 32.76% |
| Total Liquid Assets | CN¥253.18 Million | 32.76% |
Asset Resilience Insights
- Very High Liquidity: Shanghai MicuRx Pharmaceutical Co. Ltd. A maintains exceptional liquid asset reserves at 32.76% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Shanghai MicuRx Pharmaceutical Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Shanghai MicuRx Pharmaceutical Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Shanghai MicuRx Pharmaceutical Co. Ltd. A (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai MicuRx Pharmaceutical Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 24.42% | CN¥207.36 Million | CN¥849.13 Million | -42.93pp |
| 2023-12-31 | 67.35% | CN¥786.98 Million | CN¥1.17 Billion | -7.39pp |
| 2022-12-31 | 74.74% | CN¥1.12 Billion | CN¥1.50 Billion | +24.41pp |
| 2021-12-31 | 50.32% | CN¥326.36 Million | CN¥648.54 Million | -10.45pp |
| 2020-12-31 | 60.77% | CN¥410.45 Million | CN¥675.39 Million | -- |